These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34153874)

  • 21. Nose in malignant mesothelioma-Prediction of response to immune checkpoint inhibitor treatment.
    Disselhorst MJ; de Vries R; Quispel-Janssen J; Wolf-Lansdorf M; Sterk PJ; Baas P
    Eur J Cancer; 2021 Jul; 152():60-67. PubMed ID: 34087572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
    Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
    Tsao AS; Harun N; Lee JJ; Heymach J; Pisters K; Hong WK; Fujimoto J; Wistuba I
    Clin Lung Cancer; 2014 May; 15(3):197-201. PubMed ID: 24492162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
    Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
    Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.
    Berardi R; Fiordoliva I; De Lisa M; Ballatore Z; Caramanti M; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Onofri A; Cascinu S
    Tumori; 2016; 102(2):190-5. PubMed ID: 26893272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.
    Christoph DC; Asuncion BR; Mascaux C; Tran C; Lu X; Wynes MW; Gauler TC; Wohlschlaeger J; Theegarten D; Neumann V; Hepp R; Welter S; Stamatis G; Tannapfel A; Schuler M; Eberhardt WE; Hirsch FR
    J Thorac Oncol; 2012 Sep; 7(9):1440-8. PubMed ID: 22895141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
    Waterhouse DM; Nwokeji ED; Boyd M; Penrod JR; Espirito JL; Robert NJ; Daumont MJ
    Future Oncol; 2021 Jul; 17(19):2439-2448. PubMed ID: 33769073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
    Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
    Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma.
    Ghanim B; Hoda MA; Klikovits T; Winter MP; Alimohammadi A; Grusch M; Dome B; Arns M; Schenk P; Jakopovic M; Samarzija M; Brcic L; Filipits M; Laszlo V; Klepetko W; Berger W; Hegedus B
    Br J Cancer; 2014 Feb; 110(4):984-90. PubMed ID: 24434429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic and predictive role of [
    Zucali PA; Lopci E; Ceresoli GL; Giordano L; Perrino M; Ciocia G; Gianoncelli L; Lorenzi E; Simonelli M; De Vincenzo F; Setti LR; Bonifacio C; Bonomi M; Bombardieri E; Chiti A; Santoro A
    Cancer Med; 2017 Oct; 6(10):2287-2296. PubMed ID: 28941158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma.
    Yao ZH; Tian GY; Yang SX; Wan YY; Kang YM; Liu QH; Yao F; Lin DJ
    Tumour Biol; 2014 Jul; 35(7):6839-45. PubMed ID: 25051913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
    Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
    Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study.
    Takamori S; Toyokawa G; Shimokawa M; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Akamine T; Hirai F; Seto T; Tagawa T; Takenoyama M; Ichinose Y; Maehara Y
    Ann Surg Oncol; 2018 Jun; 25(6):1555-1563. PubMed ID: 29500763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
    Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
    Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.
    Raphael J; Le Teuff G; Hollebecque A; Massard C; Bahleda R; Margery J; Besse B; Soria JC; Planchard D
    Lung Cancer; 2014 Aug; 85(2):251-7. PubMed ID: 24882384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Mencoboni M; Botta M; Grossi F; Cortinovis D; Zilembo N; Ripa C; Tiseo M; Favaretto AG; Soto-Parra H; De Vincenzo F; Bruzzone A; Lorenzi E; Gianoncelli L; Ercoli B; Giordano L; Santoro A
    Br J Cancer; 2013 Aug; 109(3):552-8. PubMed ID: 23860535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study.
    Nakano T; Kuribayashi K; Kondo M; Morise M; Tada Y; Hirano K; Hayashi M; Tanaka M; Hirabayashi M
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):264-272. PubMed ID: 32893992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.
    Pass HI; Goparaju C; Espin-Garcia O; Donington J; Carbone M; Patel D; Chen Z; Feld R; Cho J; Gadgeel S; Wozniak A; Chachoua A; Leighl N; Tsao MS; de Perrot M; Xu W; Liu G
    J Thorac Oncol; 2016 Jun; 11(6):900-9. PubMed ID: 26903362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance of soluble CD26 in malignant pleural mesothelioma.
    Fujimoto N; Ohnuma K; Aoe K; Hosono O; Yamada T; Kishimoto T; Morimoto C
    PLoS One; 2014; 9(12):e115647. PubMed ID: 25526639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.